Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Mem…

Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the ...
technologynetworks

The Role of Anti-PLA2R in the Diagnosis, Monitoring and Treatment of Membranous Nephropathy: A Summary of Recent Guidelines

Recent guidelines for the management of glomerular diseases have highlighted the importance of anti-PLA2R antibody detection for MN diagnosis, monitoring and transplant evaluation. 5 A review of the ...
MarketScreener

Biohaven Ltd. Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026

Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado.
BioWorld

Biohaven’s TRAP degrader shows efficacy in membranous nephropathy models

Idiopathic membranous nephropathy (IMN) is frequently driven by autoantibodies targeting phospholipase A2 receptor 1 (PLA2R), resulting in immune-mediated glomerular injury and proteinuria.
RTTNews

Biohaven's BHV-1420 Targets PLA2R Autoantibodies In Membranous Nephropathy

In a laboratory diagnostic assay, BHV-1420 brought 88% of anti-PLA2R-positive patient samples (n=59) below the clinical threshold for positivity, indicating its potential to recognize and target ...

Biohaven Ltd. présente des données précliniques sur BHV-1420 lors de la Kidney Week 2026 de l’American Society of Nephrology

Biohaven Ltd. a présenté samedi des données précliniques sur BHV-1420 lors d’une présentation orale à l’occasion de la Kidney Week 2026 de l’American Society of Nephrology , à ...